In summary, the generation of EPH/ephrin-targeting therapeutic agents lays the foundation for the establishment of a novel, efficient therapeutic regimen, that may endorse, or even replace standard chemotherapeutic approaches, and provide better treatment options for especially aggressive BC subtypes. The gene discussed is EPHA1; the disease is breast cancer.